Sphingosine kinases are involved in the regulation of all-trans retinoic acid sensitivity of K562 chronic myeloid leukemia cells.

Oncology Letters
Defu Sun, Siping Wang

Abstract

The efficacy of all-trans retinoic acid (ATRA) for the treatment of chronic myeloid leukemia (CML) has been reported to be limited both as single-drug treatment or in combination with other drugs. Our previous study demonstrated that sphingosine 1-phosphate attenuated the effects of ATRA on human colon cancer cells by blocking the expression of retinoic acid receptor β. The aim of the present study was to investigate whether the ATRA-dependent proliferation inhibition of K562 cells was regulated by sphingosine kinases (SphKs). The results of cell proliferation assay and reverse transcription-PCR demonstrated that ATRA may exert synergistic effects with the SphK1 inhibitor SKI 5C or the pan-SphK inhibitor SKI II to inhibit the proliferation of K562 cells and upregulate the expression levels of the ATRA-inducible enzyme cytochrome P450 26A1 (CYP26A1). Knocking down the expression of SphK1 or SphK2 in K562 cells by small interfering RNA enhanced the inhibitory effects of ATRA and induced the expression of CYP26A1. Crude asterosaponins, which abrogated the expression of SphK2, also enhanced the effects of ATRA on K562 cells. In conclusion, the results of the present study demonstrated that SphKs may be involved in the regulation of...Continue Reading

References

Oct 1, 1975·Annals of Surgery·S I Schwartz
Nov 19, 1993·Cell·W S el-DeiryB Vogelstein
Sep 1, 1993·Differentiation; Research in Biological Diversity·J M KurieE Dmitrovsky
Nov 13, 2001·Oncogene·L Degos, Z Y Wang
Nov 5, 2002·Journal of Cell Science·Roberto Montesano, Priscilla Soulié
Jul 2, 2003·The Journal of Biological Chemistry·Hong LiuSarah Spiegel
Aug 20, 2003·International Journal of Cancer. Journal International Du Cancer·Yongdoo ChoiYoungro Byun
Sep 5, 2003·The Journal of Biological Chemistry·Nobuaki IgarashiShun-ichi Nakamura
Dec 30, 2004·The Journal of Experimental Medicine·Stuart M PitsonMathew A Vadas
Feb 9, 2010·Cellular and Molecular Life Sciences : CMLS·Maria TheodosiouMichael Schubert
Apr 21, 2010·The Journal of Biological Chemistry·Giuditta IlluzziAlessandro Prinetti
Jun 16, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Oscar ArrietaJaime De la Garza
Sep 30, 2010·Seminars in Hematology·John M Goldman
Jun 29, 2011·Anti-cancer Agents in Medicinal Chemistry·Stuart M PitsonClaudine S Bonder
Mar 24, 2012·Cell & Bioscience·Richard Kin Ting KamHui Zhao
Jan 17, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Roisin M ConnollySaraswati Sukumar
Mar 14, 2013·Protein & Cell·Haojian Zhang, Shaoguang Li
Jul 12, 2013·The New England Journal of Medicine·Francesco Lo-CocoUNKNOWN Study Alliance Leukemia
Sep 21, 2013·Journal of Natural Products·Nguyen Phuong ThaoYoung Ho Kim
May 23, 2015·Journal of Asian Natural Products Research·Bui Thi NgoanChau Van Minh
Jun 26, 2015·International Journal of Molecular Sciences·Rui ZhangGuoxun Chen
Feb 29, 2016·Current Hematologic Malignancy Reports·Lauren CaldemeyerLuke Akard
Oct 30, 2018·Current Hematologic Malignancy Reports·Ting ZhouShimin Hu

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.